Fig. 1From: Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstractsTCR mutations represented in the structure (A); CD3γε tetramer binding to hybridoma T cells (B) and mutant T cell hybridoma activation assayBack to article page